Prolactin up-regulates cathepsin B and D expression in minor salivary glands of patients with Sjögren's syndrome.
Various proteases are expressed in the minor salivary glands (MSG) of patients with Sjögren's syndrome (SS), and as we have already shown, prolactin is neosynthesized in the acinar cells of patients with SS. The present study aims to characterize the influence of PRL on the expression of cathepsin B and D in the MSG of patients with SS. Cathepsin B and D expression was investigated immunohistochemically in MSG of 30 patients with SS and 15 healthy volunteers. The presence of cathepsin B and D mRNAs was checked in three SS patients and three control subjects by means of reverse transcription-polymerase chain reaction (RT-PCR). The specificity of the anti-cathepsin B and D antibodies used for the immunohistochemistry was checked by means of western blotting analysis. The influence of prolactin on the immunohistochemical expression of cathepsin B and D was quantitatively assayed by computer-assisted microscopy at three different doses (5, 50, and 500 ng/ml) on eight MSGs (four control subjects and four patients with SS) maintained ex vivo under organotypic cultures. This influence was also investigated at the mRNA level. Whereas cathepsin B immunopositivity was absent from glandular epithelial cells of healthy subjects and only slightly present in SS patients, cathepsin D immunoreactivity was considerably greater (p < 0.0001) in both the acini and the ducts of patients with SS as compared with control subjects. Cathepsin B, but not D, was also expressed in about 20% of infiltrating mononuclear cells of SS patients. Treatment of both healthy and SS minor salivary glands with PRL significantly (p < 0.05 top < 0.0001) enhanced cathepsin B and D expression in acinar and ductal cells at both protein and mRNA levels. PRL produced locally in MSGs of SS patients, but not those of healthy subjects, could play a role in the pathogenesis of Sjogren's syndrome, if only through the activation of proteolytic activity on the part of cathepsins B and D.
Steinfeld
S
S
Divisions of Rheumatology, Erasme University Hospital, Brussels, Belgium.
Maho
A
A
Chaboteaux
C
C
Daelemans
P
P
Pochet
R
R
Appelboom
T
T
Kiss
R
R
D001483:Base Sequence; D016022:Case-Control Studies; D002401:Cathepsin B / Q000235:genetics*; D002402:Cathepsin D / Q000235:genetics*; D017931:DNA Primers; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009924:Organ Culture Techniques; D011388:Prolactin / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012469:Salivary Glands / Q000201:enzymology*; D012859:Sjogren's Syndrome / Q000201:enzymology*; D015854:Up-Regulation / Q000502:physiology*
D017931:DNA Primers; D012333:RNA, Messenger; D011388:Prolactin; D002401:Cathepsin B; D002402:Cathepsin D